MIT's Claim Construction Prevails In ImClone Suit
The patent in question describes a method for producing antibodies from DNA. MIT and Repligen have alleged that ImClone uses the process to manufacture its profitable cancer drug Erbitux.
During the Markman hearing in the case, ImClone had argued that one term in the patent, “tissue specific mammalian cellular enhancer,” was...
To view the full article, register now.